An Open-label, Phase 2 Randomized Trial of Camrelizumab (SHR1210) Plus Apatinib Versus Paclitaxel and Cisplatin/Carboplatin Plus Bevacizumab as a First-line Therapy in Patients With Stage IVB, Recurrent, or Persistent Cervical Cancer
Latest Information Update: 08 Oct 2021
At a glance
- Drugs Camrelizumab (Primary) ; Rivoceranib (Primary) ; Bevacizumab; Carboplatin; Cisplatin; Paclitaxel
- Indications Carcinoma; Cervical cancer; Squamous cell cancer
- Focus Therapeutic Use
- 25 Sep 2021 Status changed from not yet recruiting to recruiting.
- 27 Jul 2021 New trial record